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ApoptosisGlucocorticoids are widely used in anti-myeloma therapy and their action is potentiated by rapamycin,
a mTOR inhibitor. However, the molecular mechanisms underlying these effects remain poorly
characterized. We show here that dexamethasone (Dex)-induced apoptosis in MM.1S and OPM-2 cells
is characterized by Bax and Bak conformational changes, ΔΨm loss, cytochrome c release and caspase-3
activation. Rapamycin, which had minimal cytotoxic effect by itself, strongly potentiated Dex-induced
apoptosis. Apoptotic gene expression proﬁling showed an increase in mRNA levels of Bim in MM.1S
cells after Dex treatment and further increases in both cell lines when co-treated with rapamycin.
Western blot analysis revealed a moderate increase in Bim protein levels in both MM.1S and OPM-2
cells. Immunoprecipitation experiments revealed that most Bim was complexed to Mcl-1 in untreated
cells. Upon treatment with Dex, and specially Dex plus rapamycin, Bim–Mcl-1 complex was disrupted
and Bim was found associated to a CHAPS-insoluble fraction. Overexpression of Mcl-1 stabilized Bim–
Mcl-1 complexes upon treatment with Dex or Dex+rapamycin and fully prevented apoptosis. Gene
silencing of Bim inhibited for the most part Dex-induced apoptosis and, to a large extent, apoptosis
induced by Dex plus rapamycin. These results, taken together, indicate that Bim protein is the key
mediator of apoptosis induced by Dex and also responsible for the potentiating effect of rapamycin,
providing molecular criteria for the use of glucocorticoids combined with mTOR inhibitors in myeloma
therapy.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Glucocorticoid-containing regimes for the therapy of multiple
myeloma (MM) were introduced more than 35 years ago [1] and still
remain the most widely accepted treatment option in elderly
patients [2]. From 1992, dexamethasone (Dex) alone is also
frequently used in MM patients [3,4] and Dex has been considered
to account for most of the responses to VAD (vincristine, adriamycin,
dexamethasone) [4]. Although in 1995 it was found that the anti-
myeloma action of Dex was due to apoptosis induction [5], the
information concerning the molecular mechanism of glucocorticoid-
induced apoptosis in MM cells is still scarce. Dex-induced apoptosis
is independent of JNK activity [6] and takes place by the
mitochondrial route, since it is inhibited by Bcl-2 overexpression
[7] and occurs with down-regulation of Bcl-xL mRNA levels [8,9].
Surprisingly it was reported that apoptosis induced by Dex involvedondrial membrane potential;
tetramethylrhodamine ethyl
T-MLPA, reverse-transcriptase
34 976762123.
ll rights reserved.the mitochondrial release of Smac/Diablo but not that of cytochrome
c and, congruent with this, showed a poor caspase-3 activation
[10,11].
It has also been reported that rapamycin, a speciﬁc inhibitor of
mTOR activity, can sensitize MM cells to Dex-induced apoptosis [12].
A high-throughput microarray analysis revealed that expression of
FasL, Bim and DR5 genes was up-regulated and that of XIAP and Bcl-2
genes down-regulated in OPM-2 cells by rapamycin [13]. Western
blot analysis conﬁrmed that rapamycin reduced levels of the caspase
inhibitor XIAP [13]. However, the decrease of XIAP does not account
per se for the potentiating effect of rapamycin on Dex-induced
apoptosis. In this regard, we have recently found that rapamycin can
increase Bim protein levels in some MM cell lines and thus potentiate
apoptosis induced by interferon-α [14].
The aim of the present work was to deﬁne the key molecular
determinants of Dex-induced apoptosis in myeloma cells as well as
the mechanism underlying the apoptosis-potentiating effect of
rapamycin. We have found that the BH3-only protein Bim is the key
mediator of apoptosis induced by Dex and also responsible, for the
most part, for the potentiating effect of rapamycin. These results
provide molecular criteria to use Dex in single and combination
chemotherapy and support the combined use of mTOR inhibitors with
glucocorticoids in anti-myeloma therapy.
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2.1. Cell culture, transfections and toxicity assays
Human multiple myeloma (MM) cell lines MM.1S and MM.1R,
selected by its sensitivity and resistance, respectively, to Dex [8] were
kindly provided by Dr. Atanasio Pandiella (CIC, Salamanca). U266 and
RPMI 8226 were from ATCC and OPM-2 from DSMZ (Germany). Cells
were routinely cultured at 37 °C in RPMI 1640 medium supplemented
with 10% or 15% (OPM-2) fetal calf serum (FCS), L-glutamine and
penicillin/streptomycin (hereafter, complete medium). Mcl-1 stable-
overexpressing MM.1S cells were generated as previously described
[14]. In brief, the pLZR-IRES-GFP-Mcl-1 plasmid, encoding the full-
length human Mcl-1 cDNA (kindly provided by Dr. Xiandong Wang,
Univ. of Texas, USA), was transduced by retroviral infection. Clones
derived from single cells were obtained by limiting dilution and the
expression of Mcl-1 was analyzed byWestern blotting. Cells containing
empty vector (pLZR-IRES-GFP) were used as controls. In proliferation
assays, cells (3×105 cells/ml) were treated in ﬂat-bottom, 24-well
(1ml/well) or 96-well plates (100ml/well) with 5 μMdexamethasone
(Dex) in complete medium for the times indicated. When appropriate,
the pan-caspase inhibitor Z-VAD.fmk (100 μM, Bachem, Germany), and
themTOR inhibitor rapamycin (10 nM, Calbiochem)were added to cells
1 h prior to Dex treatment. Cell proliferation was determined by a
modiﬁcation of the MTT-reduction method [15] and viability by
microscopical inspection of Trypan blue-stained cells. Nuclear altera-
tionsduring apoptosiswere analyzed byﬂuorescencemicroscopy in cell
cultures labeled with Hoechst 33342 (Invitrogen, Barcelona, Spain).
2.2. RT-MLPA
Cellular mRNA was analyzed by reverse transcriptase multiplex
ligation-dependent probe ampliﬁcation (RT-MLPA), using SALSA MLPA
KIT R011 Apoptosis mRNA from MRC-Holland (Amsterdam, The
Netherlands) [16]. Total RNA from 5×106 cells was isolated from
myeloma cells by the RNeasy Mini Kit (Qiagen, Barcelona, Spain)
according to the manufacturer's protocol. Sample homogenization was
improved by passing the lysed cellular sample obtained with the RLT
buffer through a QiaShredder column (Qiagen). To perform RT-MLPA
analysis 200 ng of total RNA were ﬁrst reverse-transcribed using the
gene-speciﬁc probemix. The resulting cDNAwas annealed overnight at
60 °C to the MLPA probe mix, and then ligated. Ligation products were
ampliﬁedbyPCR(35 cycles, 30 s at 95 °C, 30 s at 60 °Cand1min at72 °C)
with one unlabelled and one FAM-labeled primer. The ﬁnal PCR
ampliﬁed fragments were separated by capillary electrophoresis on a
48-capillary ABI PRISM 3100 Genetic Analyzer (Applied Biosystems,
Madrid, Spain). The peak area and height were processed using
PeakScanner analysis software. The levels of mRNA for each gene were
expressed as a normalized ratio of thepeak area dividedby thepeakarea
of housekeeping control gene (β2-microglobulin). This accounted for the
relative abundanceofmRNAs of apoptotic genes. The kit contains probes
for mRNAs of 39 apoptosis-related genes. In the R011 mix, the probe
signals of, Bcl-xL, Apollon/BRUCE, Bnip3L and Mcl-1 mRNAs are
deliberately reduced by the inclusion of competitor oligonucleotides.
2.3. RNA interference assays
MM.1S cells were electroporated with siRNA oligonucleotides by
using a Nucleofector system (Amaxa, Germany) according to the
manufacturer's instructions. Brieﬂy, 3×106 cells were resuspended in
100 μl solution V containing 90 pmol double-stranded siRNAs and
electroporated with O23 program. Prewarmed cultured medium
(500 μl) was added to each cuvette and cells were transferred to plastic
dishes at 6×105 cells/ml. OPM-2 cells were transfected with HiPerFect
Transfection Reagent (Qiagen). Brieﬂy, one day prior transfection, cells
were diluted to a density of 3×105 cells/ml in complete medium. Thenext day, 4×105 cells/well in a 24-well plate were resuspended in
100 μl of complete medium. The corresponding siRNA (30 pmol/106
cells) and HiPerFect (2.5 μl/well) were added to an Eppendorf tube
containing 100 μl of mediumwithout serum per well and incubated for
10 min at room temperature. The complexes were added drop-wise
onto the cells, mixed gently and incubated at 37 °C for 6 h. Then,
completemedium(up to1ml)was added to eachwell. Transfected cells
were cultured for 6 or 36 h, as indicated, before Dex and/or rapamycin
addition and further incubated for another 24 h.
The sense strand sequences used, with two 3′-dTdT overhangs,
were as follows:
Bim-siRNA: 5′-GACCGAGAAGGUAGACAAUUG-3′
Puma-siRNA1 (p1): siGENOME SMARTpool
Puma-siRNA2 (p2): 5′-GCCTGTAAGATACTGTATA-3′
Noxa-siRNA: 5′-CUUCCGGCAGAAACUUCUG-3′
Bmf-siRNA: 5′-CAAGGTGTCATGCTGCCTT-3′
Lamin A/C-siRNA: 5′-CTGGACTTCCAGAAGAACA-3′ (negative control).
Bim, Noxa, Lamin A/C and Puma (p1) oligonucleotides were
synthesized by Dharmacon (Madrid, Spain) and Puma (p2) and Bmf
oligonucleotides were from Qiagen (Spain).
2.4. Flow cytometry analysis
Intracellular levels of FasL and activation of caspase-3 were
determined by immunolabeling with speciﬁc antibodies. After the
different treatments, cells (1×106) were ﬁxed with 4% paraformalde-
hyde in PBS (15 min, 4 °C), permeabilized with 0.1% saponin in PBS
containing 5% goat serum for 15 min and incubated for 30 min at 20 °C
with either mouse anti-human FasL mAb (NOK-1) and rabbit anti-
mouse IgG-FITC or anti active caspase 3-FITCmAb (C92-605), both from
BD Biosciences (Madrid, Spain). Cells were resuspended in 500 μl PBS
and analyzed in a ﬂow cytometer (FACScan). Apoptosis in MM.1S cells
was evaluated by the simultaneous determination of phosphatidylser-
ine (PS) exposure andmitochondrialmembrane potential (ΔΨm) in the
same cell sample. Brieﬂy, cells (2.5×105 in 200 μl) were incubated with
2 nM 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3), Invitrogen) at
37 °C for 10min in annexin-bindingbuffer (140mMNaCl, 2.5mMCaCl2,
10 mMHepes/NaOH, pH 7.4). Then, 0.4 μl annexin V-PE (Immunostep,
Salamanca, Spain) were added and incubated at room temperature for
15 min. Cell suspension was diluted to 500 μl with binding buffer and
analyzed by ﬂow cytometry. In OPM-2 cells, displaying non-speciﬁc
binding of the PE moiety of annexin V-PE, ΔΨm was determined with
tetramethylrhodamine ethyl ester (TMRE, 60nM) and PS exposurewith
annexin V-FITC (1 μl), all from Invitrogen.
Conformational changes of Bax and Bak proteins were assessed by
intracellular immunostaining using speciﬁc antibodies recognizing only
the pro-apoptotic conformation of these proteins [17]. Cells (1×106)
were cultured in the presence or absence or 5 μMDex, 10 nMrapamycin
or both for 24 h. Then, cellswere ﬁxedwith 1%paraformaldehyde in PBS
(15min, 4 °C) and incubated for 25min at room temperaturewith0.5 μg
of anti-Bax (6A7, BD Biosciences) or anti-Bak (TC100, Calbiochem) in
100 μl of PBS containing 0.1% saponin and 5% goat serum. Cells were
washed with 0.03% saponin in PBS, incubated with a FITC-labeled anti-
mouse IgG antibody (Invitrogen) and analyzed by ﬂow cytometry.
Quantitative analysis of cytochrome c release frommitochondria during
apoptosis was assayed by the method of Waterhouse and Trapani [18].
In brief, cells (1×106) were treated with 5 μM Dex in the presence or
absence of rapamycin, permeabilized with 100 μl digitonin (25–50 μg/
ml in PBS containing 100 mM KCl) for 5 min on ice, ﬁxed in 4%
paraformaldehyde in PBS and resuspended in blocking buffer (3% BSA,
0.05% saponin in PBS). Cells were incubated overnight at 4 °C with a 1/
200 dilution of anti-native cytochrome c mAb (6H2.B4, BD Biosciences)
in blocking buffer, washed, incubated with a FITC-labeled secondary
antibody and analyzed by ﬂow cytometry.
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Total protein extracts from control or treated cells (3×106) were
prepared by suspension in 400 μl CHAPS buffer (1 mM HEPES pH 7.4,
150 mM NaCl, 2% CHAPS). Cell lysates were centrifuged (13,000×g,
10 min) and supernatants subjected to immunoprecipitation with
3 μg of either mouse mAb anti-Mcl-1 (clone 22, BD biosciences) or rat
mAb anti-Bim (clone 14A8, Calbiochem), at 4 °C, overnight, with
gentle rotation. Protein–antibody complexes were recovered by
incubation with anti-mouse or anti-rat agarose-IgG beads (Sigma)
at 4 °C for 3 h and beads recovered by brief centrifugation. Beads
containing immunoprecipitates were washed three times with CHAPS
buffer and proteins released by heating for 5 min at 100 °C. Proteins
from immunoprecipitates, supernatants and pellets were analyzed by
SDS-PAGE and Western blotting using rabbit primary antibodies to
avoid detection of mouse or rat immunoglobulins. Anti-cytochrome c
oxidase, subunit I, mAb (clone 1D6E1A8, Invitrogen) was used to
localize mitochondria-rich fraction.
2.6. Western blot analysis
Levels of proteins involved in apoptosis were analyzed by Western
blotting. In general, membrane ﬁlters were sequentially analyzed for
several proteins by a multiple blotting assay method, as described [19].
After the corresponding treatments, cells were lysed in 50mMTris/HClFig. 1. Effect of dexamethasone and rapamycin on cell growth (top) and apoptosis (bottom) i
with dexamethasone (Dex, 5 μM), rapamycin (Rap, 10 nM) or both, as indicated. After 24 or 4
by measuring mitochondrial membrane potential (ΔΨm) with DiOC6(3) by ﬂow cytometrypH 7.4 buffer containing 0.15 mM NaCl, 10% glycerol, 1 mM Na3VO4,
10 mM Na4P2O7, 50 mM NaF, 1 mM EDTA, 10 mg/ml leupeptin, 1 mM
PMSF and 1% Triton X-100. Solubilized proteins from equal numbers of
Trypan-blue negative cells (3×105/lane) were resolved by SDS-15%
PAGE, transferred to PVDF membranes and incubated with primary
antibodies diluted in TBS-T (10 mM Tris/HCl pH 8.0, 0.12 M NaCl, 0.1%
Tween-20), containing 5% skimmed milk. Primary antibodies anti
human proteins used were: anti-XIAP (clone 48) and anti-Bax
(#554104) both from BD Biosciences; anti-survivin (#NB500-201,
Novus); anti-Bim (22-40, Calbiochem), anti-Bcl-2 (sc-783) and anti-
Mcl-1 (sc-819) from Santa Cruz Biotechnology; anti-Bak (#06-536,
Millipore); anti-PUMA (#4976), anti-Bmf (#4692) from Cell Signalling
and anti-Noxa (clone 114C307, Abcam).Membraneswerewashedwith
TBS-T and incubated with 0.2 μg/ml of the corresponding peroxidase-
labeled secondary antibody (Sigma) and revealed by ECL. Control of
protein loading was achieved by reprobing with anti-actin (1/10,000)
or anti-tubulin (1/10,000) (Sigma). When necessary, the intensity of
bands was quantiﬁed by densitometry by using Quantity One software
(BioRad). The intensity of each Bim isoform was normalized relative to
that of the corresponding actin band.
2.7. Statistical analysis
Analysis of signiﬁcance of results was evaluated, when necessary, by
two-tailed Student t test using GraphPad Prism 4.0 software (GraphPadnMM cells. MM.1S, MM.1R, OPM-2 and RPMI 8226 cells (300,000 cell/ml) were treated
8 h of culture, cell viability was determined by theMTT-reductionmethod and apoptosis
. Results are the mean±SD, of three to ﬁve independent determinations per point.
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were considered to be signiﬁcant (⁎), very signiﬁcant (⁎⁎) when
0.001bpb0.01, and extremely signiﬁcant (⁎⁎⁎) when pb0.001.
3. Results
3.1. Effect of Dex and rapamycin on proliferation of MM cells
Treatment with 5 μM Dex for 24–48 h caused a time-dependent
growth inhibition in sensitive MM.1S and OPM-2 cells (Fig. 1), which
was mainly due to the induction of apoptosis, characterized by loss of
ΔΨm (Fig. 1) and PS exposure (not shown). The apoptotic effect of
Dex increased with time (Fig. 1). By contrast, Dex treatment had no
signiﬁcant effect on growth and apoptosis induction in MM.1R and
RPMI 8226 cells (Fig. 1), according to published data [12]. The mTOR
inhibitor rapamycin inhibited growth of MM.1S and OPM-2 cells by
about 60% and 80%, respectively. after 48 h treatment, causing an
increase in the proportion of cells in the G1 phase of cell cycle (not
shown). Except for the PTEN null OPM-2 cells, which are stringently
dependent on the PI3K/Akt for survival [20,21], rapamycin, at the
doses used, did not induce a signiﬁcant apoptosis in any cell line
(Fig. 1). However, the combination of Dex with rapamycin strongly
potentiated Dex-induced apoptosis in MM.1S and OPM-2 cell lines,Fig. 2. Characteristics of Dex and rapamycin induced apoptosis. MM.1S and OPM-2 cells (30
24 h and analysis of (a) proapoptotic conformational changes of Bax and Bak was performed b
Cytochrome c release frommitochondria and (c) caspase-3 activation were analyzed by ﬂow
Dex, Rap or both for 40 h, as described in Experimental procedures. Speciﬁcity of caspase-
(100 μM).slightly increased the growth inhibitory effect of rapamycin in RPMI
8226 cells and had no signiﬁcant effect on MM.1R cells (Fig. 1).
U266 cells, as reported previously [12], were resistant to treatment
with Dex alone or in combination with rapamycin (data not shown).
3.2. Characteristics of apoptosis induced by Dex and Dex plus rapamycin
Dex treatment induced proapoptotic conformational changes of
Bax and Bak, which were increased by combination with
rapamycin (Fig. 2a). Dex also induced the release of appreciable
amounts of cytochrome c from mitochondria, as determined by
ﬂow cytometry, and this release was increased by rapamycin co-
treatment (Fig. 2b). Apoptosis was also characterized by a
signiﬁcant caspase-3 activation, which was fully prevented by co-
treatment with the pan-caspase inhibitor Z-VAD.fmk (Fig. 2c). Z-
VAD.fmk also prevented the development of classical apoptotic
morphology (not shown) but it only inhibited in part Dex-induced
ΔΨm loss and cell death (from 50% in the absence to 42% in the
presence of Z-VAD.fmk in MM.1S cells). When combined with Dex,
rapamycin strongly potentiated ΔΨm loss, PS exposure, Bax and
Bak conformational changes, cytochrome c release, caspase-3
activation, and apoptosis (Figs. 1 and 2). Co-treatment with Z-
VAD.fmk prevented again caspase-3 activation (Fig. 2c) but only0,000 cell/ml) were treated with either 5 μM Dex, 10 nM rapamycin (Rap) or both, for
y ﬂow cytometry with speciﬁc antibodies, as described in Experimental procedures. (b)
cytometry, with speciﬁc antibodies, in MM1.S and OPM-2 cell lines treated with either
3 activation was assessed by co-incubation with the pan-caspase inhibitor Z-VAD.fmk
Fig. 2 (continued).
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presence of Z-VAD.fmk in MM.1S cells). Z-VAD.fmk did not prevent
either Bax and Bak conformational changes or cytochrome c
release (data not shown).
Rapamycin alone had minimal effects on ΔΨm loss, PS exposure,
Bax and Bak conformational changes, cytochrome c release and
caspase-3 activation. On the other hand, the Fas/FasL system was not
involved in Dex-induced apoptosis. Flow cytometry analysis revealed
that neither OPM-2 nor MM.1S cells expressed FasL in plasma
membrane, though around 85% of OPM-2 and 95% of MM.1S cells
expressed intracellular FasL (Fig. S1). FasL levels were not signiﬁcantly
altered by treatment with Dex, rapamycin or both and blocking anti-
Fas antibodies did not prevent apoptosis induced by Dex and Dex plus
rapamycin (not shown).3.3. Effect of Dex and rapamycin in mRNA levels of apoptotic proteins
We used the RT-MLPA technique to investigate changes in
expression levels of 39 genes involved in apoptosis, mainly in the
intrinsic pathway, during treatment with Dex and rapamycin. In
MM.1S cells, Dex moderately increased the mRNA levels of the
BH3-only proteins Bim (1.6-fold) and to a lesser extent those of
Puma and Bmf, as well as those of the anti-apoptotic protein Mcl-1
(Fig. 3). Treatment with rapamycin alone for 24 h slightly increased
mRNA levels of Puma, Bcl-2 and Mcl-1. Combined treatment with
Dex and rapamycin further increased the mRNA levels of Bim
(3.8-fold), Puma, Bcl-2 and Mcl-1. Noxa mRNA levels were low and
decreased upon treatment. These reductions in Noxa mRNA levels
were also found in Dex-insensitive MM.1R cells and in low sensitive
Fig. 3. Apoptotic gene expression analysis by RT-MLPA. MM.1S and OPM-2 cells (300,000 cell/ml) remained untreated (white bars) or were treated with either 5 μM Dex, 10 nM
rapamycin (Rap) or both for the times indicated. Total RNA from of 5×106 cells was extracted as described in Experimental Procedures and 200 ng were used for RT-MLPA analysis.
The mRNA amount of all genes was normalized with respect to that of β2-microglobulin. Results are expressed as the mean±SEM of the relative mRNA expression levels from three
individual determinations in three different experiments. Statistical signiﬁcant differences of treated versus untreated cells: ⁎pb0.05; ⁎⁎pb0.01 and ⁎⁎⁎pb0.001.
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mRNA levels were found in MM.1R and RPMI 8226 cells treated
with either Dex or Dex+rapamycin (Fig. S2). RT-MLPA analysis of
OPM-2 cells showed a slight increase in transcriptional activity of
the Bim gene after 24 h treatment with Dex, which was greatly
increased by co-treatment with rapamycin (Fig. 3). The combination
of Dex and rapamycin also increased Noxa mRNA levels in this cell
line. Puma mRNA levels remained very low in any experimental
condition and, as found in MM.1S cells, those of Mcl-1 increased
(Fig. 3).
3.4. Effect of Dex and rapamycin on levels of apoptotic proteins
Changes in levels of relevant apoptotic proteins were analyzed by
Western blot. In MM.1S cells, treatment with Dex increased BimL
levels and the combination of Dex+rapamycin increased those of
BimL and BimS nearly two-fold (Fig. 4). Mcl-1 levels also slightly
increased after Dex or rapamycin treatment and were reduced by
Dex and rapamycin combination (Fig. 4), according to the high
caspase-3 activation observed (Fig. 2c). Dex and rapamycin did not
signiﬁcantly change levels of XIAP and survivin (Fig. 4) but
combined treatment with Dex and rapamycin greatly reduced levels
of these proteins. Levels of Puma-β increased slightly after 24 h
treatment with either Dex or rapamycin but combined treatment
with Dex and rapamycin led to an abrupt decrease in levels of this
protein. MM.1S cells expressed very low levels of Noxa and they did
not increase upon treatment. In OPM-2 cells, levels of all Bim
isoforms increased by 24 h of incubation with Dex. Combined
treatment with Dex and rapamycin increased levels of BimL andBimS isoforms, although to a lesser extent than those observed in
MM.1S cells (Fig. 4). Levels of Mcl-1 did not signiﬁcantly change
after treatment with either Dex or rapamycin and were slightly
reduced by the combined treatment (Fig. 4). Noxa was signiﬁcantly
expressed by OPM-2 cells under basal conditions and their levels
decreased during treatment with Dex or rapamycin (Fig. 4). Levels
of XIAP and survivin decreased in cells treated with Dex and
rapamycin (Fig. 4) coinciding in time with the increase in caspase-3
activation and apoptosis (Fig. 2c). No signiﬁcant changes in Bim
protein levels were found in MM.1R and RPMI 8226 cells treated
with Dex or Dex+rapamycin (Fig. S3).
3.5. Interaction between Bim and Mcl-1 during Dex-induced apoptosis
Since it has been reported that Mcl-1 acts as a natural antagonist of
Bim in myeloma and leukemia cells [22,23] we analyzed the effect of
Mcl-1 overexpression on Dex-induced cell death. Apoptosis induced
by Dex in the presence or absence of rapamycin, after 24 or 48 h
treatment, was fully prevented by overexpression of the anti-
apoptotic protein Mcl-1 (Fig. 5). To gain insight into the mechanism
of apoptosis induction by Bim and its blocking by Mcl-1, co-
immunoprecipitation experiments were performed (Fig. 6). When
Mcl-1 was immunoprecipitated, most Bim was associated to Mcl-1 in
untreated MM.1S cells (Fig. 6a). Low amounts of Bim were found in
the supernatant and CHAPS-insoluble membrane pellet. WhenMM.1S
cells were treated with Dex and immunoprecipitated with anti-Mcl-1,
the amount of Bim in IP supernatants and that associated to
membrane insoluble fraction, slightly increased (Fig. 6a). Treatment
with rapamycin alone gave a distribution pattern similar to that of
Fig. 4. Levels of Bcl-2 family and other apoptotic proteins in cells treated with Dex and/or rapamycin. MM.1S and OPM-2 cells were treated with either 5 μMDex, 10 nM rapamycin or
both, for 24 h. Cells (3×105/lane) were lysed in 1% Triton X-100 buffer and levels of relevant apoptotic proteins analyzed by SDS-PAGE andWestern blotting with speciﬁc antibodies.
Actin or tubulin were used as loading markers and are shown at the top of each blotting membrane analyzed, as indicated. The percentage of cell death, determined by Trypan-blue
staining, is indicated in each case. Densitometric analysis of Bim levels (normalized to those of actin), corresponding to the blots shown, was performed by using Quantity One
software.
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which the total amount of Mcl-1 in Triton X-100 cell lysates decreased
(Fig. 4), the relative amount of Bim bound to Mcl-1 decreased and a
signiﬁcant amount of Bim was recovered in the CHAPS-insoluble
membrane pellet (Fig. 6b). Similar results, concerning the association
of Bim with Mcl-1 and the association of Bim with CHAPS-insoluble
membrane pellet, were obtained when Bim was immunoprecipitated
(Fig. 6b). No signiﬁcant interaction of Bim with Bak, Bax (Fig. 6b) or
Bcl-xL (data not shown) could be noticed by immunoprecipitation in
cells either untreated or treated with Dex. Immunoprecipitation of
Bim in MM.1S cells overexpressing Mcl-1 (MM.1S/Mcl-1) revealed
that this protein remained bound to Mcl-1 in untreated cells and
cells treated with Dex or with Dex+rapamycin, in agreement with
the lack of apoptosis observed. No association of Bim to membrane
pelletwas found in cells overexpressingMcl-1under any experimental
condition (Fig. 6c).3.6. Effect of gene silencing of BH3-only proteins on Dex-induced
apoptosis
To further precise the role of BH3-only proteins in Dex-induced
apoptosis, we transfected myeloma cells with siRNAs for Bim, Puma,
Noxa and Bmf. Down-regulation of Bim protein levels in MM.1S cells
by transfection with Bim-siRNA (Fig. 7a) prevented virtually all of
Dex-induced toxicity and reduced apoptosis induced by Dex and
rapamycin by about 50% (Fig. 7b). Unexpectedly, Puma-siRNA1 probe
mix caused increases in basal Bim levels (Fig. S4a) and increased Dex-
induced apoptosis (Fig. S4b) at 24 h. A comparable effect was
previously reported with a similar probe Puma-siRNA mix [24].
Transfection with Puma-siRNA2 caused a slight, but signiﬁcant
(pb0.05) protective effect in cells treated with Dex or Dex plus
rapamycin, but it slightly decreased Bim levels (Fig. 7a). Combined
transfection with Bim-siRNA and Puma-siRNA2 did not signiﬁcantly
Fig. 5. Effect of Mcl-1 overexpression on Dex-induced apoptosis. MM.1S/pLZR andMM.1S/Mcl-1 cells were treated for 24 or 48 h with either 5 μMDex, 10 nM rapamycin or both, as
indicated, and apoptosis evaluated by determining ΔΨm with TMRE by FACS analysis. A single representative experiment, out of three of each experimental condition, is shown.
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with Dex and rapamycin (data not shown). Western blot analysis
conﬁrmed the reduction in levels of Bim and Puma-α in cells
transfected with the corresponding siRNAs at the indicated time
(Fig. 7a). Gene silencing with Bmf-siRNA had no signiﬁcant effect on
apoptosis induced by Dex alone or in combination with rapamycin
(Fig. S5).
In OPM-2 cells, transfectionwith Bim siRNA also abrogatedmost of
the toxicity induced by Dex alone (pb0.05) and around 50% of
apoptosis caused by Dex in combination with rapamycin. Bim gene
silencing efﬁciently reduced Bim levels (mainly BimL and BimS)
during treatment with Dex, rapamycin or both (Fig. 7c). Since OPM-2
cells expressed signiﬁcant Noxa levels (Fig. 4) and treatmentwith Dex
and rapamycin increased the relative amount of Noxa mRNA (Fig. 3)
we also analyzed the effect of Noxa gene silencing in apoptosis. Noxa
siRNA treatment reduced Noxa basal levels but it did not prevent
apoptosis induced with Dex plus rapamycin (Fig. 7b, c).
4. Discussion
Glucocorticoids have been used for more than 35 years in MM
therapy and in particular in elderly patients [2]. Dexamethasone,
alone or combined with thalidomide, lenalidomide or bortezomib, is
used in patients subjected to high-dose therapy [25]. Recently it has
been reported that rapamycin, a speciﬁc inhibitor of mTOR, sensitizes
MM cells to Dex-induced apoptosis [12,13]. However, the lack of a
molecular explanation for this sensitization and even of the detailedmolecular mechanism of Dex-induced apoptosis in MM cells,
seriously hamper the use of this combination in therapy.
It was reported that Dex-induced apoptosis in MM cells was
inhibited by Bcl-2 overexpression [7] and entailed the mitochondrial
release of Smac/Diablo, but not that of cytochrome c, leading to a poor
caspase-3 activation [10,11]. Experiments using oligonucleotide
arrays have indicated that Dex treatment down-regulated Bcl-xL
mRNA levels in MM cells [8,9]. However, there is no information
available concerning what proteins are the key inducers of apoptosis.
Our current results indicate that Dex-induced apoptosis fulﬁlls the
molecular characteristics of the intrinsic pathway of apoptosis,
including Bax and Bak conformational changes, loss of ΔΨm, and PS
exposure. Moreover, by using sensitive ﬂow cytometric assays, we
have detected themitochondrial release of cytochrome c and caspase-
3 activation after Dex treatment. We also conﬁrm the previously
reported reduction in Bcl-xL mRNA levels in MM.1S cells treated with
Dex, though levels of Bcl-xL protein remained roughly constant. More
important, we have found a signiﬁcant increase both at the mRNA and
to a lesser extent, protein level, of the BH3-only protein Bim [26]
during apoptosis. This suggested that Bim could be the responsible for
triggering the proapoptotic conformational changes of Bax and Bak
and the release of apoptotic mediators from mitochondria. The fact
that more Bak than Bax underwent Dex-induced conformational
changes in OPM-2 cells suggests that the role of Bak is more important
in the induction of apoptosis in this particular cell line. A preferential
implication of Bak over Bax has been previously found in other
process of Bim-induced apoptosis [14]. Immunoprecipitation and
Fig. 6. Evaluation of Bim-Mcl-1 interaction during apoptosis. MM.1S cells (5×106 per point) were left untreated (C) or incubated for 24 hwith 5 μMDex (D), 10 nM rapamycin (R) or
both (D+R), homogenized in a 2% CHAPS-containing buffer and subjected to immunoprecipitation with (a) anti-Mcl-1 (clone 22) or (b) anti-Bim (clone 14A8) antibodies, as
indicated. Insoluble membrane pellets, immunoprecipitation supernatants and immunoprecipitates (IP) were analyzed by SDS-PAGE and Western blot and revealed with anti-Bim,
anti-Mcl-1, anti-Bak and anti-Bax antibodies. Mitochondrial membrane fraction was identiﬁed with aid of an anti-cytochrome c oxidase, subunit I (COX I), mAb. (c) MM.1S cells
overexpressing Mcl-1 protein (MM.1S/Mcl-1) were homogenized in 2% CHAPS-containing buffer, immunoprecipitated with anti-Bim antibody and analyzed by western blot with
anti-Mcl-1 and anti-Bim antibodies as in b As shown in the left panel, MM.1S/Mcl-1 cells overexpress an alternative splicing Mcl-1 isoform [39], marked with an ⁎, which retains the
ability to bind Bim. In all cases, results from a single representative experiment, out of ﬁve, is shown.
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this apoptosis (see later).
According to previous reports [12], the apoptotic ability of Dex
was greatly potentiated by cotreatment with rapamycin. Growth
inhibition caused by rapamycin alone in either Dex-sensitive or
resistant MM cell lines was mainly due to cell cycle arrest. We have
found that co-treatment with rapamycin greatly increased ΔΨmloss, caspase-3 activation PS exposure and apoptosis in Dex-
sensitive cells. In a previous work, in an attempt to identify the
molecular determinants of rapamycin sensitization, the translational
state of apoptosis-regulating proteins was analyzed. By using a
high-throughput microarray methodology [13], an increase in
mRNA translational efﬁciency for FasL, Bim and p53, and a decrease
in that of XIAP was observed in OPM-2 cells treated with
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decrease of XIAP protein levels but no increases of levels or
activities of proapoptotic proteins were detected [13]. In this regard,
we have found that MM.1S and OPM-2 cells express FasL in
cytoplasm but not in plasma membrane, and that levels of this
protein did not change after Dex or rapamycin treatment. The
possible participation of Apo2L/TRAIL can also be ruled out since we
previously reported that rapamycin does not affect to TRAIL-
induced apoptosis [27] while increasing Bim protein levels [14] in
MM cells. We also conﬁrm the reduction in XIAP levels in OPM-2
cells upon treatment with rapamycin and we have also found aFig. 7. Effect of gene silencing of Bim or Puma on Dex-induced apoptosis in MM.1S cells. (a)
Puma or Noxa, as indicated, with a Nucleofector (MM.1S) or with HiPerFect reagent (OPM-2
Western blotting to verify protein silencing. (b) Cells were then treated with either 5 μMDex
TMRE by ﬂow cytometry. (c)Western blot analysis of Bim (MM.1S) or Bim and Noxa (OPM-2
of three, is shown.decrease in mRNA and protein levels of survivin, another IAP
protein. More important, we have found that the BH3-only protein
Bim is the key mediator of Dex-induced apoptosis and of its
potentiation by rapamycin. By using a sensitive RT-MLPA analysis,
and in agreement with the previous work [13], we have found that
Bim mRNA levels increase in MM cells treated with Dex alone or in
combination with rapamycin. Western blot analysis show a
moderate increase in Bim protein levels in those cells. The
importance of Bim as critical mediator of apoptosis induced by
Dex and responsible for the potentiating effect of rapamycin was
also supported by co-immunoprecipitation and gene-silencingMM.1S and OPM-2 cells were transfected with the siRNAs for Lamin A/C (control), Bim,
). Transfected cells were cultured for the times indicated and protein levels analyzed by
, 10 nM rapamycin or both, for 24 h, and apoptosis determined by measuring ΔΨmwith
) proteins in cells treated for 24 hwith Dex and/or rapamycin. A representative blot, out
Fig. 7 (continued).
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and behaves as a natural antagonist of Bim proapoptotic function
[22,28]. In MM cells, Dex treatment, and in a greater extent Dex+
rapamycin, induced the release of Bim from Mcl-1 and its
association with a CHAPS-insoluble fraction containing Bak and
membrane mitochondrial markers. This accumulation of Bim in the
“mitochondria-rich,” insoluble cell fraction, upon apoptosis induc-
tion has been previously reported by others [29]. To further clarify
the respective role of Bim and Mcl-1 in Dex-induced apoptosis, we
also analyzed the interaction of Bim and Mcl-1 in MM cells
overexpressing Mcl-1. When these cells were treated with Dex or
Dex+rapamycin, Bim remained associated to Mcl-1, it was not
found in the CHAPS-insoluble fraction and apoptosis was blocked.
On the other hand, it has been reported that, once released from
Mcl-1, Bim can activate Bax and/or Bak [30,31]. Direct association
between Bax or Bak with Bim in model systems has also been
described [30,32]. However, direct association of Bim or other BH3-
only proteins in cells under physiological conditions has not
convincingly demonstrated [33], suggesting that any putative direct
binding between Bim and Bax/Bak is presumably short-lived. Our
present results agree with this hypothesis and with results from
previous studies [29]. Also according to these results, transfection
with Bim siRNA abrogated Dex-induced apoptosis in MM.1S and
OPM-2 cells and also most of the potentiating effect of rapamycin.
The slight protective effect of Puma-siRNA2 in MM.1S cells treated
with Dex or Dex+rapamycin was associated with a slight decrease
in Bim levels, perhaps due to an off-target effect. Anyway, a smallcontribution of Puma to apoptosis cannot be ruled out. Alternatively,
and since Bim silencing did not fully protect from apoptosis induced by
Dex+rapamycin another uncharacterized BH3-only, Mcl-1-interact-
ing protein can be responsible for the potentiating effect of rapamycin.
In this connection, IM-9 cells, a B-leukemia considered to be for many
years amyeloma, express functional glucocorticoid receptors (GR) but
are insensitive to the apoptotic action of Dex [34,35]. These facts can be
explained by our current results, since IM-9 cells express very low
levels of Bim mRNA that are not increased by Dex treatment (Fig. S2),
and do not express Bim protein [17].
A very recent report has investigated the mechanism of Dex-
induced apoptosis in MM.1S cells by using MM.1R-resistant cells
transfected with different glucocorticoid receptor (GR) mutants [36].
According to our present results, re-expression of wild-type GR in
MM.1R cells induced Bim expression and apoptosis. However, cells
transfected with a mutant GR that neither binds to DNA nor induces
transactivation [37], still up-regulated BimuponDex treatment but did
not undergo apoptosis. This is a rather puzzling result but a possible
explanation would be that those particular clones would express
higher amounts of Mcl-1 than parental cells. Last, but not least, our
results agree with the ﬁnding that B-lymphocytes from Bim-deﬁcient
mice are protected from dexamethasone-induced apoptosis [38].
In summary, our results indicate that the BH3-only protein Bim is
the key mediator of apoptosis induced in myeloma cells by Dex and
also of its potentiation by the mTOR inhibitor rapamycin. Our results
also suggest that Mcl-1 is the main anti-apoptotic protein charged of
neutralizing Bim action. Last, but not least, these data provide
322 N. López-Royuela et al. / Biochimica et Biophysica Acta 1803 (2010) 311–322molecular criteria for the use of Dex alone or combined with
rapamycin in myeloma therapy.
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